EU approves Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for 1st-line advanced ER-positive breast cancer – AstraZeneca
AstraZeneca’s Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union for the treatment of adult… read more.
